Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS-II Prevention: anastrozole versus placebo for breast cancer prevention in high-risk postmenopausal women
ISRCTN31488319Phase 3Completed
- Sponsor
- Queen Mary University of London
- Start
- May 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Anastrozole with Placebo (2 arms). Primary endpoint: Breast cancer incidence. Started May 2003; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN31488319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31488319.